Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

NVIDIA

Tesla

As an investor, finding stocks that can make you rich is as easy as making good choices and sticking by them. There are just some stocks that are going to keep winning, even if they fall back a little bit.

3 Stocks to Buy for Life-Changing Wealth Potential

Kellogg

As the three-ring circus of rising interest rates, inflation, and bank failures plays out, corporate spinoffs and separations are worthy of investor consideration.

3M, Danaher, and Kellogg Are Spinoff Stock Plays

Disney

General Electric

With their extensive reach, here are three conglomerates' investors may want to consider as they are top-rated Zack stocks at the moment.

Time to Buy Stock in These Conglomerates?

WASHINGTON , April 10, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its 5.00% Series B Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's common stock on April 17, 2023 (the "Conversion Date"). The conversion rate for each share of Preferred Stock will be 5.0175 shares of the Company's common stock.

Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock

Apple

Accenture Plc

Adobe

Advanced Micro Devices

Amazon

Broadcom

Alibaba

Salesforce

Ford Motor Company

General Motors

Alphabet

JD.com

London Stock Exchange Group PLC

Moody's

MercadoLibre

MSCI

Microsoft

QUALCOMM

S&P Global

Texas Instruments

UnitedHealth Group

In this article, I will introduce you to 10 growth companies which I currently consider to be attractive. The selected picks have shown significant growth over the past years and all of them are in strong financial health.

My Top 10 Growth Companies To Invest In April 2023

The DBS initiatives, cost management actions and steady demand across major end markets augur well for Danaher's (DHR) growth. Handsome rewards to shareholders add to the stock's appeal.

Here's Why You Should Hold on to Danaher (DHR) Stock Now

WASHINGTON , March 27, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Danaher Schedules First Quarter 2023 Earnings Conference Call

ICON

Icon's double digit earnings growth forecast should drive its stock price. IQVIA's increased operational efficiency and earnings growth should drive its share price.

2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch

Air Products and Chemicals

Camden Property

Amdocs

Equity LifeStyle Properties

Essex Property Trust

First Industrial Realty Trust

FirstService

Globe Life Inc

Hannon Armstrong Sustainable Infrastructure Capital

Humana

Monolithic Power Systems

Nutrien

Rexford Industrial Realty

Schwab US Dividend Equity ETF

Steel Dynamics

Stantec

TC Energy

Willis Towers Watson PLC

All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 11.0% and a median increase of 8.4%.

18 Upcoming Dividend Increases To Finish Q1

Extra Space Storage

Home Depot

Norfolk Southern

Union Pacific

Markets are in turmoil. Volatility is high and the Fed is in a tough spot. In addition to discussing macroeconomic developments, I explain my strategy and thought process when it comes to buying quality dividend growth stocks.

Capitalizing On Chaos: My Aggressive Move To Buy More Of These 5 Dividend Growth Wonders

Old Dominion Freight Line

Zoetis

Markets are in turmoil. Hence, in this article, we start with a discussion of the risks facing investors and why I believe in attractive buying opportunities this year. While I understand that investors often opt for higher-yielding investments, I will explain why investments in low-yielding dividend-growth stocks come with benefits.

3 Awesome Dividend Growth Stocks To Buy During A Bear Market

Hitachi Ltd

HTHIY vs. DHR: Which Stock Is the Better Value Option?

HTHIY vs. DHR: Which Stock Should Value Investors Buy Now?

Cognizant Technology Solutions

Diamondback Energy

Nokia

Pfizer

The equities market continues to be incredibly volatile. Investors were optimistic following a robust rally in Jan.; all major U.S. indices are down since then.

The 7 Most Undervalued Stocks to Buy in March 2023

WASHINGTON , March 7, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced a strategic partnership with the University of Pennsylvania (Penn) focusing on cell therapy innovation. The multi-year partnership aims to develop new technologies that will improve the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of next generation engineered cell products.

Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies

In this article, we discuss one of my favorite dividend growth stocks, which makes up for a low yield by being a consistent source of outperforming total returns. The company has a stellar high-moat M&A-driven business model with strong pricing power and often anti-cyclical customers.

Danaher: The Secret To Successful (Dividend) Investing

Danaher has benefited from the Covid-19 period. The company has seen strong (earnings) growth, and it's positioned to maintain this.

Danaher: Compounder Starts To Look Attractive

Enbridge

Intuit

Johnson & Johnson

Lockheed Martin

Altria

PepsiCo

SPDR S&P 500 ETF Trust

Thermo Fisher Scientific

Vanguard Total Stock Market ETF

Verizon

We start with a discussion of diversification theories based on the findings of a scientific article called "The Dividend Puzzle". While inexperienced investors should stick to ETFs, there's a clear case to be made for the behavioral approach, which is based on a mix of different dividend strategies.

The Dividend Pyramid: Potentially Beat The Market With This 12-Stock Portfolio

WASHINGTON , Feb. 22, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 28, 2023 to holders of record on March 31, 2023. In addition, the Board of Directors has approved a quarterly cash dividend of $12.50 per share of its 5.00% Series B Mandatory Convertible Preferred Stock, payable on April 17, 2023 to holders of record on March 31, 2023.

Danaher Announces Quarterly Dividends

News for Danaher Stock (DHR)